SPRY Stockholders with Large Losses Should Contact Robbins LLP About Leading the ARS Pharmaceuticals Inc. Class Action Before the October 5, 2026 Deadline

ARS Pharmaceuticals faces a securities class action alleging it failed to disclose risks to obtaining expanded CVS Caremark coverage for neffy by the July 1, 2026 target. CVS deferred its coverage decision to January 2027, leaving neffy without expanded coverage during the summer and back-to-school allergy seasons; ARS shares allegedly fell 23.9%, from $10.54 on June 24 to $8.02 the following day. The lead-plaintiff filing deadline is October 5, 2026.

Analysis

The litigation notice itself is not a fundamental catalyst; the investable issue is a six-month formulary-access gap during the highest-value prescription-initiation window. For SPRY, missed seasonal starts can have an outsized effect because allergy products rely on caregiver, school, and physician adoption cycles; prescriptions deferred into January are not fully recoverable if patients default to incumbent auto-injectors or if prescribers avoid writing a product with uncertain coverage. The key downside is therefore not only near-term revenue but a weaker 2027 refill base and a higher commercial-spend requirement to rebuild demand.

CVS has negligible direct earnings exposure, but its delayed decision increases payer concentration risk for SPRY: a favorable January outcome would still leave the company dependent on a small number of PBM/formulary wins to validate launch economics. The relevant competitive beneficiary is VTRS, whose EpiPen franchise retains lower-friction access and established school/physician behavior; even modest incremental persistence among existing auto-injector users can stabilize an otherwise mature franchise. Watch for whether other major PBMs follow CVS's timing rather than approving independently, as synchronized delays would turn an isolated access issue into a broader commercialization reset.

Consensus may overemphasize legal liability and underweight the binary January formulary decision. Securities claims typically create limited cash-flow exposure relative to a commercial-stage biotech's access and execution risk, whereas a positive CVS decision could generate a sharp relief rally from depressed expectations. The thesis is falsified by evidence that cash-pay demand, non-CVS covered lives, or prescription growth offset the lost seasonal channel; absent that evidence, estimates for 2027 adoption likely remain vulnerable over the next one to two earnings cycles.

Key Decisions for Investors

• Avoid treating the class-action deadline as a trading catalyst; maintain no standalone CVS position on this news because the financial exposure is immaterial.
• For existing SPRY longs, reduce exposure or hedge through the next earnings update unless management discloses weekly prescription trends, covered-life growth, and cash-burn guidance that demonstrate demand resilience without the delayed formulary channel.
• Tactical relative-value watch: long VTRS versus short SPRY over the next 1-3 months only if SPRY borrow is available and liquid; the trade expresses access-driven share retention by EpiPen. Exit if SPRY reports material non-CVS coverage gains or prescription growth that closes the access gap.
• Do not initiate a fresh SPRY short solely after the drawdown; wait for the next guidance revision or prescription-data read. A January favorable coverage decision is a discrete upside catalyst that makes unhedged short risk asymmetric, so put spreads are preferable to naked downside exposure if implied volatility is reasonable.